
    
      This is a Phase 2a Proof-of-Concept (POC) study. The study will enroll approximately 62
      patients randomized 1:1 into either the UBX1325 or sham study arms, in order to assess the
      primary objective. All patients will be followed for approximately 24 weeks.
    
  